Influence of gene polymorphism of sulphonylurea receptor 1 on glucose-reducing effect of gliclazide
- Author:
Li-Li CHEN
1
Author Information
1. Department of Endocrinology and Metabolism
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus;
Gliclazide;
Polymorphism;
Single nucleotide;
Sulphonylureas;
Type 2
- From:
Academic Journal of Second Military Medical University
2010;28(7):765-767
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To study the common single nucleotide polymorphism (SNPs) of sulphonylurea receptor 1 (SUR1) gene (16-3c/t and S1369A) and its relationship with the glucose-reducing effect of gliclazide. Methods: A total of 115 patients with type 2 diabetes were enrolled in this 8-week, open-label, cohort study. All patients were required to take gliclazide for 8 weeks. FPG, HbA1c and insulin were assayed before and after therapy and HOMA-B and HOMA-IR indices were calculated to assess the therapeutic effects of gliclazide. The gene polymorphism of SUR1 was analyzed by Taq-Man technology and the effects of gliclazide were compared between patients with different phenotypes. Results: (1) The study was completed in 101 of the 115 patients and the frequencies of c and t alleles were 0.54 and 0.44, A and S were 0.58 and 0.42, respectively. (2) FPG, HbA1c and HOMA-B indices were significantly improved after therapy in patients with all kinds of genotypes (P<0.05); HOMA-IR indices had no significant change after therapy(P>0.05). (3) The changes of HbA1c and HOMA-B indices of t/t group were more obvious than those of c/c and c/t groups (P<0.05). S1369A polymorphism had no association with the effect of gliclazide(P>0.05). Conclusion: The polymorphism of SUR1 can influence the glucose-reducing effect of gliclazide and this influence might be associated with loci of SNPs.
